SlideShare une entreprise Scribd logo
1  sur  49
Télécharger pour lire hors ligne
Presentor : Dr.Kumar
Moderator :Dr.K.Chaitanya
Renal ReplacementTherapy
Introduction
It is estimated that a third of patients in the critical care
setting have an AKI and approximately 5% will require
renal replacement therapy .
The hospital mortality in patients with an AKI requiring RRT
is as high as 60%.
no specific treatments have been shown to reverse the
course of AKI, so RRT forms the basis of further
management
Definition
Acute kidney injury (AKI), is defined as an abrupt (within
48 hours) reduction in kidney function.
The AKI network defines the reduction in kidney function as
the presence of any one of the following:
1. An absolute increase in serum creatinine of ≥ 0.3 mg.dl -1(≥
26.4 mcmol.l-1)
2. A percentage increase in serum creatinine of ≥ 50% (1.5-fold
from baseline)
3. A reduction in urine output (< 0.5 ml.kg -1 per hour for
more than six hours).
Indications of RRT
Acute kidney injury (AKI)with
1. Fluid overload (refractory to diuretics)
2. Hyperkalemia (K+ > 6.5)
3. Severe metabolic acidosis (pH < 7.1)
4. Rapidly climbing urea/creatinine (or urea > 30mmol.l -1)
5. Symptomatic uraemia: encephalopathy, pericarditis,
bleeding, nausea, pruritus
6. Oliguria/anuria
Contd..
Overdose with a dialyzable drug or toxin .
drugs are cleared by RRT if they are water-soluble and not highly
protein-bound
contd
Severe sepsis
 patients with ARF have severe sepsis, multiorgan
dysfunction and a major systemic inflammatory response.
 to remove or adsorb inflammatory mediators which cause
organ dysfunction may represent yet another reason for its
preferential application
Dialyzer unit
 The basic components of the dialyzer unit:
 Dialyzer – cellulose, substituted cellulose, synthetic non cellulose membranes.
 Dialysis solution – dialysate : water must remain free of Al, Cu, chloramines,
bacteria and endotoxin.
 Tubing for transport of blood and dialysis solution.
 Machine to power and mechanically monitor the procedure
 Air monitor
 Proportioning system
 Temperature sensor
 Urea sensror to calculate clearance.
 The basic components of the dialyzer unit:
 Dialyzer – cellulose, substituted cellulose, synthetic non cellulose membranes.
 Dialysis solution – dialysate : water must remain free of Al, Cu, chloramines,
bacteria and endotoxin.
 Tubing for transport of blood and dialysis solution.
 Machine to power and mechanically monitor the procedure
 Air monitor
 Proportioning system
 Temperature sensor
 Urea sensror to calculate clearance.
Renal replacement therapy
MECHANISM OF SOLUTE REMOVAL
Haemofiltration
involves blood being pumped
through an extracorporeal
system that incorporates a semi-
permeable membrane.
 The hydrostatic pressure that is
created on the blood-side of the
filter drives plasma water across
the filter.
 This process is referred to as
“ULTRAFILTRATION”.
Molecules that are small enough to pass through the
membrane (<50,000 Daltons) are dragged across the
membrane with the water by the process of
CONVECTION.
The filtered fluid (ultrafiltrate) is discarded and a
replacement fluid is added in an adjustable fashion according
to the desired fluid balance.
Haemodialysis
involves blood being pumped through
an extracorporeal system that
incorporates a dialyzer.
In the dialyzer, blood is separated
from a crystalloid solution (dialysate)
by a semi-permeable membrane.
Solutes move across the membrane
along their concentration gradient
from one compartment to the other
obeying Fick`s laws of diffusion.
For example, bicarbonate moves from
dialysate to blood whereas urea and
potassium move from blood to dialysate.
 In order to maintain concentration
gradients and therefore enhance the
efficiency of the system the dialysate flows
countercurrent to the flow of blood.
When removal of water is required the
pressure on the blood-side of the membrane
has to be increased forcing water molecules
to pass into the dialysate.
Haemodiafiltration
 as its name suggests, is a combination of filtration and dialysis.
 It has the benefits of both techniques but to a lesser extent than
when the individual techniques are used on their own.
There is no evidence to suggest that CVVDF has a survival benefit
when compared to CVVH but may be a useful way of increasing
clearance of small solutes.
Slow continuous ultrafiltration
It is used when the only requirement is water removal.
Effectively, it is CVVH with a low filtration rate.
 It can remove up to 6 litres of fluid a day but solute removal
is minimal.
Modes of Renal Replacement Techniques
Intermittent ContinuousHybrid
IHDIHD
Intermittent
haemodialysis
SLEDDSLEDD
Sustained (or slow)
low efficiency daily
dialysis
SLEDD-FSLEDD-F
Sustained (or slow)
low efficiency daily
dialysis with filtration
CVVHCVVH
Continuous veno-venous
haemofiltration
CVVHDCVVHD
Continuous veno-venous
haemodialysis
CVVHDFCVVHDF
Continuous veno-venous
haemodiafiltration
SCUFSCUF
Slow continuous
ultrafiltration
Continuous versus intermittent renal
replacement therapy
The typical intensive care patient requiring renal replacement
therapy have some of the following characteristics,
• they are older
• multisystem organ failure consisting of sepsis
• cardiac failure
• adult respiratory distress syndrome
• gastrointestinal bleeding
• liver abnormalities.
 They are generally hypercatabolic, hypermetabolic and require
ventilatory support and large amounts of fluid intake to administer
inotropes, medications and nutrition.
This volume of fluid is administered in the context of a low urine
output and increased lung water.
This necessitates the need for fluid removal and when
implemented with intermittent HD, large amounts of fluid are
removed over a small period of time resulting in haemodynamic
instability
Intermittent haemodialysis
Intermittent haemodialysis involves dialysing with higher flow
rates than CRRT for defined periods of time.
 A typical regime is 3-5 hours of dialysis 3 times a week.
The high flow rates and rapid fall in plasma osmolality mean that
it is only suitable for patients who are cardiovascularly stable.
It forms the basis of long term RRT for chronic renal failure but
is not often used in the critical care setting.
Intermittent Therapies
Major complications of IHD
Systemic hypotension
Arrhythmia
Hypoxaemia
Haemorrhage
Infection
Line-related complications(e.g. pneumothorax)
Seizure or dialysis disequilibrium
Pyrogen reaction or haemolysis
?Delay in recovery of renal function
Continous Renal replacement therapy
SCUF
• High flux membranes
• Up to 24 hrs per day
• Objective VOLUME control
• NotNot suitable for solute clearance
• Blood flow 50-200 ml/min
• UF rate 2-8 ml/min
• High flux membranes
• Up to 24 hrs per day
• Objective VOLUME control
• NotNot suitable for solute clearance
• Blood flow 50-200 ml/min
• UF rate 2-8 ml/min
CAVVH
• Extended duration up to weeks
• High flux membranes
• Mainly convectiveconvective clearance
• UF > volume control amount
• Excess UF replacedreplaced
• Replacement pre- or post-filter
• Blood flow 50-200 ml/min
• UF rate 10-60 ml/min
• Extended duration up to weeks
• High flux membranes
• Mainly convectiveconvective clearance
• UF > volume control amount
• Excess UF replacedreplaced
• Replacement pre- or post-filter
• Blood flow 50-200 ml/min
• UF rate 10-60 ml/min
CAVVHD
• Mid/high flux membranes
• Extended period up to weeks
• DiffusiveDiffusive solute clearance
• Countercurrent dialysate
• UF for volume control
• Blood flow 50-200 ml/min
• UF rate 1-8 ml/min
• Dialysate flow 15-60 ml/min
• Mid/high flux membranes
• Extended period up to weeks
• DiffusiveDiffusive solute clearance
• Countercurrent dialysate
• UF for volume control
• Blood flow 50-200 ml/min
• UF rate 1-8 ml/min
• Dialysate flow 15-60 ml/min
Other Benefits of CRRT
 Its ability to reduce energy expenditure by cooling the
febrile patient,
in the patient with heart failure resistant to diuretics,
continuous ultrafiltration can produce a rise in cardiac
index,while avoiding a fall in arterial pressure.
The haemodynamic improvement is mostlydue to a change
in preload which optimises myocardial contractility onthe
Starlingcurve
Sustained low efficiency dialysis
 aims to combine the logistic and cost advantages of IHD
with the relative cardiovascular stability of CRRT.
 Treatments are intermittent but usually daily and with
longer session durations than conventional IHD.
Solute and fluid removal are slower than IHD, but faster than
CRRT.
Renal replacement therapy
WHICH FORM OF RRT SHOULD WE USE?
What we want to remove from the plasma
2. The patient`s cardiovascular status
• CRRT causes less rapid fluid shifts and is the preferred option if there
is any degree of cardiovascular instability.
3. The availability of resources
• CRRT is more labour intensive and more expensive than IHD
• Availability of equipment may dictate the form of RRT.
4. The clinician`s experience
• It is wise to use a form of RRT that is familiar to all the staff involved.
5. Other specific clinical considerations
• Convective modes of RRT may be beneficial if the patient has septic
shock
• CRRT can aid feeding regimes by improving fluid management
• CRRT may be associated with better cerebral perfusion in patients
with an acute brain injury or fulminant hepatic failure.
Vascular access in HD/CRRT
Site Advantages disadvantages
IJV Straight access Swings in flow associated
with respiration.
Subclavian Least association with
infection.
Most comfortable
Swings in flow as above.
Subclavian vein stenosis if
catheter indwelling for a
long time.
Risks of pneumothorax
Femoral Ease of access Infection rates high.
Dialysate Fluid
 Bicarbonate buffer solutions is used in IHD to replenish
serum bicarbonate levels and neutralise metabolic acids that are
usually present in patients with renal failure.
Acetate buffer solutions present the body with a large
acetate load to be metabolised by the skeletal muscle.
In critically ill patients the acetate levels rise due to decreased
skeletal muscle metabolism.
Increased acetate levels have been associated with hypotension
and hypoxia due to its negative inotrope effect and vasodilatation
Lactate buffer soulutions
Renal replacement therapy
Extra corporeal circuit
Most CRRT techniques utilise a pump driven venovenous circuit
as this provides a high constant flow rate
Anticoagulation
extracorporeal circuit will activate coagulation pathways and the
premature clotting of a filter is a common problem.
Even a small amount of clot formation will reduce filter
performance.
NON-PHARMACOLOGICAL MEASURES
1. adequate central venous pressure,
2. optimising vascular access
3. adding a proportion of the replacement fluid to the patients
blood before it passes through the haemofilter (this is predilution)
GUIDELINES FOR NO
ANTICOAGULATION
There is a already a degree of coagulopathy
INR > 2-2.5
 APTT > 60 seconds
 platelet count < 60 x 10³.mm3
There is a high risk of bleeding
The patient is receiving activated protein C.
PHARMACOLOGICAL MEASURES
Unfractionated or low molecular weight heparins
Unfractionated heparin (UFH) [5-30kDa] is the most commonly
used anticoagulant
typical regime involves a 40-70 IU.kg-1 bolus followed by a pre-
filterinfusion at 5-10 IU.kg.-1hr-1
It is the most cost effective anticoagulant and is fully reversible
with protamine.
The APTT should be monitored to avoid excessive anti-
coagulation but there is no evidence that elevating the APTT
prolongs filter life.
Low molecular weight heparins (LMWH) [4.5-6kDa]
They are dependant on renal elimination so in this setting
their dosing needs to be guided by anti-factor Xa levels
(aiming for 0.25-0.35 IU.ml-1
 The half life of LMWHs is longer than for UFH (2-6 hrs
versus 1.5-3hrs) and their effect can only be partially
reversed with protamine.
There is not a huge amount of data on the use of LMWH in
CRRT and there is no evidence to suggest that they are
superior to UFH.
Prostaglandins
Prostaglandins (prostacyclin or prostaglandin E2) inhibit platelet
function and can either be used on their own or in combination
with heparin they have a synergistic effect.
 short half life (several minutes) so are administered as an infusion
(2.5 – 10 ng/kg/.min). The
anticoagulant effect stops within 2 hours of discontinuing the
infusion
The main side effect is vasodilation which may include a reduction
in HPV leading to hypoxemia.
they are expensive and so are only used as second line therapy
Regional citrate anticoagulation
It is an effective therapy especially when there is an increased risk
of bleeding.
It is alternative to heparin
Sodium citrate is infused into the circuit pre-filter which chelates
calcium and inhibits clot formation.
The calcium citrate complex is freely filtered so a calcium infusion
is required post-filter.
This form of anticoagulation is limited by the metabolic
derangements that it can cause: Hypocalcaemia,
hypomagnesaemia , hypernatraemia , metabolic alkalosis (citrate is
metabolised to bicarbonate), metabolic acidosis (caused by the
citrate especially if the body`s citrate handling is impaired e.g.
Filters
Filters are either cellulose-based or synthetic.
Synthetic filters such as polysulphone and polyamide are
more biocompatible and are higher-flux membranes so seem
more suitable for CRRT
high-flux membranes with a surface area of 0.6– 1.2m2 and
a pore size allowing the passage of molecules up to 50,000
Daltons
Properties
Biocompatibility
o The degree to which the membrane will activate the patient`s
inflammatory and coagulation pathways.
o The greater the biocompatibility of a membrane the less activation
it will cause
Flux
o The permeability of the filter. High flux membranes are
hydrophobic and may have more or larger pores allowing more
water and solute to move across the membrane.
Adsorption
o The ability of larger solutes to adhere to the surface of the membrane.
o A highly adsorptive membrane offers the potential benefit of adsorbing
mid sized molecules including inflammatory mediators but only until it
is saturated with them (usually after the first few hours)
Thickness
o Thinner membranes allow greater movement of solute by diffusion and
also favour convective movement
Surface area
o The surface area of the membrane determines the available area for
diffusion and ultrafiltration
Complications common to IHD, CRRT,
and hybrid therapies
1. Complications related to the vascath (including line-related
sepsis)
2. Haemodynamic instability
3. Air emboli
4. Platelet consumption
5. Blood loss
6. Electrolyte imbalances
7. Hypothermia
8. Effects of anticoagulation (bleeding or specific side-effects of the
anticoagulant used e.g. heparin induced thrombocytopenia).
Adequacy of Dialysis
 Precise standards and goals of dialysis adequacy are based on
the clearance of urea.
 The volume of distribution of urea reflects the total body water.
 Mathematical modeling based on the changing blood
concentrations
Dialysis dose
1. Measuring fractional reduction of BUN with each dialysis.
Measured by volume adjusted fractional clearance of urea.
K*t ÷ V urea
Where K – dialyzer urea clearance
t – time on dialysis
V – volume of distribution of urea
Dialysis dose
2. Measurement of urea removed through each dialysis.
% of reduction in urea during single hemodialysis treatment –
Urea reduction ratio
[1-(post dialysis BUN concentration) ] x 100
(pre dialysis BUN concentration)
Care of patients receiving hemodialysis
Variable Goals
Dialysis dose Urea kinetics model
Fluid balance Individualised. Intradialytic weight gain should be less than 5%
of IBW
Quality Measure endotoxin and bacteria in the dialysate water
Anemia Target a Hb of 10-12gms%. Avoid high dose erythropoietin
Vascular access Monitoring. To establish AV access rather than indwelling
catheters.
Bone & Mineral Calcium levels between 8.4-9.5 and a PO4 3.5-5.5mg/dl
Blood pressure Optimum targets & strategies not well defined
LDL cholesterol <100mg/dl
Quality of life indices Support from the medical social worker
Renal replacement therapy
Renal replacement therapy

Contenu connexe

Tendances

Dialyisis disequilibrium syndrome
Dialyisis disequilibrium syndromeDialyisis disequilibrium syndrome
Dialyisis disequilibrium syndromesaihari17
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapyaratimohan
 
Hyponatremia ppt .final
Hyponatremia ppt .finalHyponatremia ppt .final
Hyponatremia ppt .finalArun Karmakar
 
Continuous renal replacement therapy crrt
Continuous renal replacement therapy crrtContinuous renal replacement therapy crrt
Continuous renal replacement therapy crrtMEEQAT HOSPITAL
 
Basic principles of hemodialysis final
Basic principles of hemodialysis finalBasic principles of hemodialysis final
Basic principles of hemodialysis finalFarragBahbah
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapyHAMAD DHUHAYR
 
Complications of hemodialysis
Complications of hemodialysisComplications of hemodialysis
Complications of hemodialysisReynel Dan
 
Dialysis dose prescription (the basics) dr ujjawal
Dialysis dose prescription (the basics) dr ujjawalDialysis dose prescription (the basics) dr ujjawal
Dialysis dose prescription (the basics) dr ujjawalUjjawal Roy
 
Anticoagulation in hemodialysis
Anticoagulation in hemodialysisAnticoagulation in hemodialysis
Anticoagulation in hemodialysisVishal Ramteke
 
Adequacy of Hemodialysis
Adequacy of HemodialysisAdequacy of Hemodialysis
Adequacy of HemodialysisMNDU net
 
Kidney Transplantation
Kidney TransplantationKidney Transplantation
Kidney TransplantationMohammed Rajab
 
Continuous renal replacement therapy
Continuous renal replacement therapyContinuous renal replacement therapy
Continuous renal replacement therapysaheli chakraborty
 
ADEQUACY OF HEMODIALYSIS
ADEQUACY OF HEMODIALYSISADEQUACY OF HEMODIALYSIS
ADEQUACY OF HEMODIALYSISsaihari17
 

Tendances (20)

Dialyisis disequilibrium syndrome
Dialyisis disequilibrium syndromeDialyisis disequilibrium syndrome
Dialyisis disequilibrium syndrome
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
 
Hyponatremia ppt .final
Hyponatremia ppt .finalHyponatremia ppt .final
Hyponatremia ppt .final
 
Continuous renal replacement therapy crrt
Continuous renal replacement therapy crrtContinuous renal replacement therapy crrt
Continuous renal replacement therapy crrt
 
Crrt in aki
Crrt in akiCrrt in aki
Crrt in aki
 
Basic principles of hemodialysis final
Basic principles of hemodialysis finalBasic principles of hemodialysis final
Basic principles of hemodialysis final
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
 
hypernatremia
hypernatremiahypernatremia
hypernatremia
 
Complications of hemodialysis
Complications of hemodialysisComplications of hemodialysis
Complications of hemodialysis
 
Acute kidney injury
Acute kidney injuryAcute kidney injury
Acute kidney injury
 
Dialysis dose prescription (the basics) dr ujjawal
Dialysis dose prescription (the basics) dr ujjawalDialysis dose prescription (the basics) dr ujjawal
Dialysis dose prescription (the basics) dr ujjawal
 
Anticoagulation in hemodialysis
Anticoagulation in hemodialysisAnticoagulation in hemodialysis
Anticoagulation in hemodialysis
 
Adequacy of Hemodialysis
Adequacy of HemodialysisAdequacy of Hemodialysis
Adequacy of Hemodialysis
 
Hyponatremia
HyponatremiaHyponatremia
Hyponatremia
 
Kidney Transplantation
Kidney TransplantationKidney Transplantation
Kidney Transplantation
 
Continuous renal replacement therapy
Continuous renal replacement therapyContinuous renal replacement therapy
Continuous renal replacement therapy
 
ADEQUACY OF HEMODIALYSIS
ADEQUACY OF HEMODIALYSISADEQUACY OF HEMODIALYSIS
ADEQUACY OF HEMODIALYSIS
 
Dialysis prescription
Dialysis prescriptionDialysis prescription
Dialysis prescription
 
hyponatremia
hyponatremiahyponatremia
hyponatremia
 
Hyperkalemia
HyperkalemiaHyperkalemia
Hyperkalemia
 

En vedette

Renal replacement therapy in intensive care
Renal replacement therapy in intensive careRenal replacement therapy in intensive care
Renal replacement therapy in intensive careAndrew Ferguson
 
Dialysis for Acute Renal Failure in Critically Ill Patients
Dialysis for Acute Renal Failure in Critically Ill PatientsDialysis for Acute Renal Failure in Critically Ill Patients
Dialysis for Acute Renal Failure in Critically Ill PatientsYazan Kherallah
 
Prof. J.P.Das Oration HEART FAILURE
Prof. J.P.Das Oration HEART FAILUREProf. J.P.Das Oration HEART FAILURE
Prof. J.P.Das Oration HEART FAILUREdrucsamal
 
Focal Glomerulosclerosis
Focal GlomerulosclerosisFocal Glomerulosclerosis
Focal Glomerulosclerosisedwinchowyw
 
Renal Replacement Therapies
Renal Replacement TherapiesRenal Replacement Therapies
Renal Replacement Therapiesaungp
 
Hepatitis C in kidney transplantation
Hepatitis C in kidney transplantationHepatitis C in kidney transplantation
Hepatitis C in kidney transplantationSalwa Ibrahim
 
Kidney disorders, Laboratory Investigation and Renal Function Tests
Kidney disorders, Laboratory Investigation and Renal Function TestsKidney disorders, Laboratory Investigation and Renal Function Tests
Kidney disorders, Laboratory Investigation and Renal Function TestsMadhukar Vedantham
 
Renal biopsy, nadia
Renal biopsy, nadiaRenal biopsy, nadia
Renal biopsy, nadiaFarragBahbah
 
Review of new alerts on PROTON PUMP INHIBITORS (PPI) adverse effects 2016 UPD...
Review of new alerts on PROTON PUMP INHIBITORS (PPI) adverse effects 2016 UPD...Review of new alerts on PROTON PUMP INHIBITORS (PPI) adverse effects 2016 UPD...
Review of new alerts on PROTON PUMP INHIBITORS (PPI) adverse effects 2016 UPD...PAWAN V. KULKARNI
 
Kidney function test
Kidney function testKidney function test
Kidney function testGavin Yap
 
Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS)Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS)Tauhid Bhuiyan
 
Focal & segmental glomerulosclerosis
Focal & segmental glomerulosclerosisFocal & segmental glomerulosclerosis
Focal & segmental glomerulosclerosisMohammad Manzoor
 

En vedette (20)

RRT
RRTRRT
RRT
 
Renal replacement therapy in intensive care
Renal replacement therapy in intensive careRenal replacement therapy in intensive care
Renal replacement therapy in intensive care
 
Dialysis for Acute Renal Failure in Critically Ill Patients
Dialysis for Acute Renal Failure in Critically Ill PatientsDialysis for Acute Renal Failure in Critically Ill Patients
Dialysis for Acute Renal Failure in Critically Ill Patients
 
Prof. J.P.Das Oration HEART FAILURE
Prof. J.P.Das Oration HEART FAILUREProf. J.P.Das Oration HEART FAILURE
Prof. J.P.Das Oration HEART FAILURE
 
Focal Glomerulosclerosis
Focal GlomerulosclerosisFocal Glomerulosclerosis
Focal Glomerulosclerosis
 
Renal Replacement Therapies
Renal Replacement TherapiesRenal Replacement Therapies
Renal Replacement Therapies
 
Kidney
KidneyKidney
Kidney
 
Hepatitis C in kidney transplantation
Hepatitis C in kidney transplantationHepatitis C in kidney transplantation
Hepatitis C in kidney transplantation
 
Renal Replacement therapy
Renal Replacement therapyRenal Replacement therapy
Renal Replacement therapy
 
Kidney disorders, Laboratory Investigation and Renal Function Tests
Kidney disorders, Laboratory Investigation and Renal Function TestsKidney disorders, Laboratory Investigation and Renal Function Tests
Kidney disorders, Laboratory Investigation and Renal Function Tests
 
Renal biopsy, nadia
Renal biopsy, nadiaRenal biopsy, nadia
Renal biopsy, nadia
 
Review of new alerts on PROTON PUMP INHIBITORS (PPI) adverse effects 2016 UPD...
Review of new alerts on PROTON PUMP INHIBITORS (PPI) adverse effects 2016 UPD...Review of new alerts on PROTON PUMP INHIBITORS (PPI) adverse effects 2016 UPD...
Review of new alerts on PROTON PUMP INHIBITORS (PPI) adverse effects 2016 UPD...
 
Renal biopsy
Renal biopsyRenal biopsy
Renal biopsy
 
Fsgs
FsgsFsgs
Fsgs
 
Obstructive uropathy+urolithias
Obstructive uropathy+urolithiasObstructive uropathy+urolithias
Obstructive uropathy+urolithias
 
Nsf
NsfNsf
Nsf
 
Cystic disease of the kidney
Cystic disease of the kidneyCystic disease of the kidney
Cystic disease of the kidney
 
Kidney function test
Kidney function testKidney function test
Kidney function test
 
Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS)Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS)
 
Focal & segmental glomerulosclerosis
Focal & segmental glomerulosclerosisFocal & segmental glomerulosclerosis
Focal & segmental glomerulosclerosis
 

Similaire à Renal replacement therapy

Basics of Hemodialysis & CRRT.pptx
Basics of Hemodialysis & CRRT.pptxBasics of Hemodialysis & CRRT.pptx
Basics of Hemodialysis & CRRT.pptxNavin Vincent
 
Dialysis Prescription In Renal Failure.pdf
Dialysis Prescription In Renal Failure.pdfDialysis Prescription In Renal Failure.pdf
Dialysis Prescription In Renal Failure.pdfSomnath Das Gupta
 
Basics of Continuous Renal Replacement Therapy
Basics of Continuous Renal Replacement Therapy Basics of Continuous Renal Replacement Therapy
Basics of Continuous Renal Replacement Therapy Muhammad Asim Rana
 
CUSTOMISING FLUIDS IN CHRONIC KIDNEY DISEASE
CUSTOMISING FLUIDS IN CHRONIC KIDNEY DISEASECUSTOMISING FLUIDS IN CHRONIC KIDNEY DISEASE
CUSTOMISING FLUIDS IN CHRONIC KIDNEY DISEASEPallavi Ahluwalia
 
Salon b 13 kasim 15.45 17.00 yusuf savran-ing
Salon b 13 kasim 15.45 17.00 yusuf savran-ingSalon b 13 kasim 15.45 17.00 yusuf savran-ing
Salon b 13 kasim 15.45 17.00 yusuf savran-ingtyfngnc
 
Dialysis various modalities and indices used
Dialysis various modalities and indices usedDialysis various modalities and indices used
Dialysis various modalities and indices usedAbhay Mange
 
Continuous rrt and its role in critically ill patients [autosaved]
Continuous rrt and its role in critically ill patients [autosaved]Continuous rrt and its role in critically ill patients [autosaved]
Continuous rrt and its role in critically ill patients [autosaved]Harsh shaH
 
Crrt 2-sharm-el-shaikh-2017-dr.-osama-el shahat-final
Crrt 2-sharm-el-shaikh-2017-dr.-osama-el shahat-finalCrrt 2-sharm-el-shaikh-2017-dr.-osama-el shahat-final
Crrt 2-sharm-el-shaikh-2017-dr.-osama-el shahat-finalFarragBahbah
 
Dialytic support for aki
Dialytic support for akiDialytic support for aki
Dialytic support for akiFarragBahbah
 
Intravascular_Fluid_Therapy_anesthesia__b7ca9904.ppt
Intravascular_Fluid_Therapy_anesthesia__b7ca9904.pptIntravascular_Fluid_Therapy_anesthesia__b7ca9904.ppt
Intravascular_Fluid_Therapy_anesthesia__b7ca9904.pptssuserd1e243
 
Crrt sudan 2017 dr. osama el shahat
Crrt sudan 2017  dr. osama el shahatCrrt sudan 2017  dr. osama el shahat
Crrt sudan 2017 dr. osama el shahatFarragBahbah
 

Similaire à Renal replacement therapy (20)

Basics of Hemodialysis & CRRT.pptx
Basics of Hemodialysis & CRRT.pptxBasics of Hemodialysis & CRRT.pptx
Basics of Hemodialysis & CRRT.pptx
 
Rrt dr.sarmistha
Rrt dr.sarmisthaRrt dr.sarmistha
Rrt dr.sarmistha
 
Dialysis Prescription In Renal Failure.pdf
Dialysis Prescription In Renal Failure.pdfDialysis Prescription In Renal Failure.pdf
Dialysis Prescription In Renal Failure.pdf
 
Kamc crrt training
Kamc crrt trainingKamc crrt training
Kamc crrt training
 
Basics of Continuous Renal Replacement Therapy
Basics of Continuous Renal Replacement Therapy Basics of Continuous Renal Replacement Therapy
Basics of Continuous Renal Replacement Therapy
 
Continuous Renal Replacement Therapy
Continuous Renal Replacement TherapyContinuous Renal Replacement Therapy
Continuous Renal Replacement Therapy
 
Seminar on CRRT
Seminar on CRRTSeminar on CRRT
Seminar on CRRT
 
CUSTOMISING FLUIDS IN CHRONIC KIDNEY DISEASE
CUSTOMISING FLUIDS IN CHRONIC KIDNEY DISEASECUSTOMISING FLUIDS IN CHRONIC KIDNEY DISEASE
CUSTOMISING FLUIDS IN CHRONIC KIDNEY DISEASE
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
 
Salon b 13 kasim 15.45 17.00 yusuf savran-ing
Salon b 13 kasim 15.45 17.00 yusuf savran-ingSalon b 13 kasim 15.45 17.00 yusuf savran-ing
Salon b 13 kasim 15.45 17.00 yusuf savran-ing
 
Dialysis various modalities and indices used
Dialysis various modalities and indices usedDialysis various modalities and indices used
Dialysis various modalities and indices used
 
Continuous rrt and its role in critically ill patients [autosaved]
Continuous rrt and its role in critically ill patients [autosaved]Continuous rrt and its role in critically ill patients [autosaved]
Continuous rrt and its role in critically ill patients [autosaved]
 
CRRT for ICU nurses
CRRT for ICU nursesCRRT for ICU nurses
CRRT for ICU nurses
 
Crrt 2-sharm-el-shaikh-2017-dr.-osama-el shahat-final
Crrt 2-sharm-el-shaikh-2017-dr.-osama-el shahat-finalCrrt 2-sharm-el-shaikh-2017-dr.-osama-el shahat-final
Crrt 2-sharm-el-shaikh-2017-dr.-osama-el shahat-final
 
CRRT .pdf
CRRT .pdfCRRT .pdf
CRRT .pdf
 
Dialytic support for aki
Dialytic support for akiDialytic support for aki
Dialytic support for aki
 
Dialytic support for AKI
Dialytic support for AKIDialytic support for AKI
Dialytic support for AKI
 
Dialytic support for AKI
Dialytic support for AKIDialytic support for AKI
Dialytic support for AKI
 
Intravascular_Fluid_Therapy_anesthesia__b7ca9904.ppt
Intravascular_Fluid_Therapy_anesthesia__b7ca9904.pptIntravascular_Fluid_Therapy_anesthesia__b7ca9904.ppt
Intravascular_Fluid_Therapy_anesthesia__b7ca9904.ppt
 
Crrt sudan 2017 dr. osama el shahat
Crrt sudan 2017  dr. osama el shahatCrrt sudan 2017  dr. osama el shahat
Crrt sudan 2017 dr. osama el shahat
 

Plus de Dr Kumar

Anaesthesia for robotic surgery
Anaesthesia for robotic surgeryAnaesthesia for robotic surgery
Anaesthesia for robotic surgeryDr Kumar
 
Telemedicine in Anaesthesia
Telemedicine in AnaesthesiaTelemedicine in Anaesthesia
Telemedicine in AnaesthesiaDr Kumar
 
TOURNIQUET AND ITS EFFECTS
TOURNIQUET AND ITS EFFECTS TOURNIQUET AND ITS EFFECTS
TOURNIQUET AND ITS EFFECTS Dr Kumar
 
Supra glottic airway children
Supra glottic airway childrenSupra glottic airway children
Supra glottic airway childrenDr Kumar
 
Scavenging system in operating room
Scavenging system in operating roomScavenging system in operating room
Scavenging system in operating roomDr Kumar
 
Pheochromocytoma and its anaesthetic management
Pheochromocytoma and its anaesthetic managementPheochromocytoma and its anaesthetic management
Pheochromocytoma and its anaesthetic managementDr Kumar
 
Neuromuscular weakness related to critical illness
Neuromuscular weakness related to critical illnessNeuromuscular weakness related to critical illness
Neuromuscular weakness related to critical illnessDr Kumar
 
Mechanisms of cerebral injury and cerebral protection
Mechanisms of cerebral injury and cerebral protectionMechanisms of cerebral injury and cerebral protection
Mechanisms of cerebral injury and cerebral protectionDr Kumar
 
Latex allergy and its management
Latex allergy and its managementLatex allergy and its management
Latex allergy and its managementDr Kumar
 
Intra operative hypoxia and hypercarbia
Intra operative hypoxia and hypercarbiaIntra operative hypoxia and hypercarbia
Intra operative hypoxia and hypercarbiaDr Kumar
 
Hypotensive anesthesia
Hypotensive anesthesiaHypotensive anesthesia
Hypotensive anesthesiaDr Kumar
 
Hypertension , crf post renal transplant patient for surgery
Hypertension , crf post renal transplant patient for surgeryHypertension , crf post renal transplant patient for surgery
Hypertension , crf post renal transplant patient for surgeryDr Kumar
 
Extubation problems and its management
Extubation problems and its managementExtubation problems and its management
Extubation problems and its managementDr Kumar
 
Effects of anaesthesia on immune system
Effects of anaesthesia on immune systemEffects of anaesthesia on immune system
Effects of anaesthesia on immune systemDr Kumar
 
Buffers in the body
Buffers in the bodyBuffers in the body
Buffers in the bodyDr Kumar
 
Anaesthetic management of conjoined twins’
Anaesthetic management of conjoined twins’Anaesthetic management of conjoined twins’
Anaesthetic management of conjoined twins’Dr Kumar
 
Anaesthesia for interventional neuroradiology
Anaesthesia for interventional neuroradiologyAnaesthesia for interventional neuroradiology
Anaesthesia for interventional neuroradiologyDr Kumar
 
Ambulatory anaesthesia
Ambulatory anaesthesiaAmbulatory anaesthesia
Ambulatory anaesthesiaDr Kumar
 
Acute pain and its management
Acute pain and its managementAcute pain and its management
Acute pain and its managementDr Kumar
 

Plus de Dr Kumar (20)

Anaesthesia for robotic surgery
Anaesthesia for robotic surgeryAnaesthesia for robotic surgery
Anaesthesia for robotic surgery
 
Telemedicine in Anaesthesia
Telemedicine in AnaesthesiaTelemedicine in Anaesthesia
Telemedicine in Anaesthesia
 
TOURNIQUET AND ITS EFFECTS
TOURNIQUET AND ITS EFFECTS TOURNIQUET AND ITS EFFECTS
TOURNIQUET AND ITS EFFECTS
 
Supra glottic airway children
Supra glottic airway childrenSupra glottic airway children
Supra glottic airway children
 
shock
shock shock
shock
 
Scavenging system in operating room
Scavenging system in operating roomScavenging system in operating room
Scavenging system in operating room
 
Pheochromocytoma and its anaesthetic management
Pheochromocytoma and its anaesthetic managementPheochromocytoma and its anaesthetic management
Pheochromocytoma and its anaesthetic management
 
Neuromuscular weakness related to critical illness
Neuromuscular weakness related to critical illnessNeuromuscular weakness related to critical illness
Neuromuscular weakness related to critical illness
 
Mechanisms of cerebral injury and cerebral protection
Mechanisms of cerebral injury and cerebral protectionMechanisms of cerebral injury and cerebral protection
Mechanisms of cerebral injury and cerebral protection
 
Latex allergy and its management
Latex allergy and its managementLatex allergy and its management
Latex allergy and its management
 
Intra operative hypoxia and hypercarbia
Intra operative hypoxia and hypercarbiaIntra operative hypoxia and hypercarbia
Intra operative hypoxia and hypercarbia
 
Hypotensive anesthesia
Hypotensive anesthesiaHypotensive anesthesia
Hypotensive anesthesia
 
Hypertension , crf post renal transplant patient for surgery
Hypertension , crf post renal transplant patient for surgeryHypertension , crf post renal transplant patient for surgery
Hypertension , crf post renal transplant patient for surgery
 
Extubation problems and its management
Extubation problems and its managementExtubation problems and its management
Extubation problems and its management
 
Effects of anaesthesia on immune system
Effects of anaesthesia on immune systemEffects of anaesthesia on immune system
Effects of anaesthesia on immune system
 
Buffers in the body
Buffers in the bodyBuffers in the body
Buffers in the body
 
Anaesthetic management of conjoined twins’
Anaesthetic management of conjoined twins’Anaesthetic management of conjoined twins’
Anaesthetic management of conjoined twins’
 
Anaesthesia for interventional neuroradiology
Anaesthesia for interventional neuroradiologyAnaesthesia for interventional neuroradiology
Anaesthesia for interventional neuroradiology
 
Ambulatory anaesthesia
Ambulatory anaesthesiaAmbulatory anaesthesia
Ambulatory anaesthesia
 
Acute pain and its management
Acute pain and its managementAcute pain and its management
Acute pain and its management
 

Dernier

historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingAnonymous
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfMedicoseAcademics
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisNilofarRasheed1
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 

Dernier (20)

historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_Wellbeing
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdf
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid Arthritis
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 

Renal replacement therapy

  • 1. Presentor : Dr.Kumar Moderator :Dr.K.Chaitanya Renal ReplacementTherapy
  • 2. Introduction It is estimated that a third of patients in the critical care setting have an AKI and approximately 5% will require renal replacement therapy . The hospital mortality in patients with an AKI requiring RRT is as high as 60%. no specific treatments have been shown to reverse the course of AKI, so RRT forms the basis of further management
  • 3. Definition Acute kidney injury (AKI), is defined as an abrupt (within 48 hours) reduction in kidney function. The AKI network defines the reduction in kidney function as the presence of any one of the following: 1. An absolute increase in serum creatinine of ≥ 0.3 mg.dl -1(≥ 26.4 mcmol.l-1) 2. A percentage increase in serum creatinine of ≥ 50% (1.5-fold from baseline) 3. A reduction in urine output (< 0.5 ml.kg -1 per hour for more than six hours).
  • 4. Indications of RRT Acute kidney injury (AKI)with 1. Fluid overload (refractory to diuretics) 2. Hyperkalemia (K+ > 6.5) 3. Severe metabolic acidosis (pH < 7.1) 4. Rapidly climbing urea/creatinine (or urea > 30mmol.l -1) 5. Symptomatic uraemia: encephalopathy, pericarditis, bleeding, nausea, pruritus 6. Oliguria/anuria
  • 5. Contd.. Overdose with a dialyzable drug or toxin . drugs are cleared by RRT if they are water-soluble and not highly protein-bound
  • 6. contd Severe sepsis  patients with ARF have severe sepsis, multiorgan dysfunction and a major systemic inflammatory response.  to remove or adsorb inflammatory mediators which cause organ dysfunction may represent yet another reason for its preferential application
  • 7. Dialyzer unit  The basic components of the dialyzer unit:  Dialyzer – cellulose, substituted cellulose, synthetic non cellulose membranes.  Dialysis solution – dialysate : water must remain free of Al, Cu, chloramines, bacteria and endotoxin.  Tubing for transport of blood and dialysis solution.  Machine to power and mechanically monitor the procedure  Air monitor  Proportioning system  Temperature sensor  Urea sensror to calculate clearance.  The basic components of the dialyzer unit:  Dialyzer – cellulose, substituted cellulose, synthetic non cellulose membranes.  Dialysis solution – dialysate : water must remain free of Al, Cu, chloramines, bacteria and endotoxin.  Tubing for transport of blood and dialysis solution.  Machine to power and mechanically monitor the procedure  Air monitor  Proportioning system  Temperature sensor  Urea sensror to calculate clearance.
  • 9. MECHANISM OF SOLUTE REMOVAL Haemofiltration involves blood being pumped through an extracorporeal system that incorporates a semi- permeable membrane.  The hydrostatic pressure that is created on the blood-side of the filter drives plasma water across the filter.  This process is referred to as “ULTRAFILTRATION”.
  • 10. Molecules that are small enough to pass through the membrane (<50,000 Daltons) are dragged across the membrane with the water by the process of CONVECTION. The filtered fluid (ultrafiltrate) is discarded and a replacement fluid is added in an adjustable fashion according to the desired fluid balance.
  • 11. Haemodialysis involves blood being pumped through an extracorporeal system that incorporates a dialyzer. In the dialyzer, blood is separated from a crystalloid solution (dialysate) by a semi-permeable membrane. Solutes move across the membrane along their concentration gradient from one compartment to the other obeying Fick`s laws of diffusion.
  • 12. For example, bicarbonate moves from dialysate to blood whereas urea and potassium move from blood to dialysate.  In order to maintain concentration gradients and therefore enhance the efficiency of the system the dialysate flows countercurrent to the flow of blood. When removal of water is required the pressure on the blood-side of the membrane has to be increased forcing water molecules to pass into the dialysate.
  • 13. Haemodiafiltration  as its name suggests, is a combination of filtration and dialysis.  It has the benefits of both techniques but to a lesser extent than when the individual techniques are used on their own. There is no evidence to suggest that CVVDF has a survival benefit when compared to CVVH but may be a useful way of increasing clearance of small solutes.
  • 14. Slow continuous ultrafiltration It is used when the only requirement is water removal. Effectively, it is CVVH with a low filtration rate.  It can remove up to 6 litres of fluid a day but solute removal is minimal.
  • 15. Modes of Renal Replacement Techniques Intermittent ContinuousHybrid IHDIHD Intermittent haemodialysis SLEDDSLEDD Sustained (or slow) low efficiency daily dialysis SLEDD-FSLEDD-F Sustained (or slow) low efficiency daily dialysis with filtration CVVHCVVH Continuous veno-venous haemofiltration CVVHDCVVHD Continuous veno-venous haemodialysis CVVHDFCVVHDF Continuous veno-venous haemodiafiltration SCUFSCUF Slow continuous ultrafiltration
  • 16. Continuous versus intermittent renal replacement therapy The typical intensive care patient requiring renal replacement therapy have some of the following characteristics, • they are older • multisystem organ failure consisting of sepsis • cardiac failure • adult respiratory distress syndrome • gastrointestinal bleeding • liver abnormalities.
  • 17.  They are generally hypercatabolic, hypermetabolic and require ventilatory support and large amounts of fluid intake to administer inotropes, medications and nutrition. This volume of fluid is administered in the context of a low urine output and increased lung water. This necessitates the need for fluid removal and when implemented with intermittent HD, large amounts of fluid are removed over a small period of time resulting in haemodynamic instability
  • 18. Intermittent haemodialysis Intermittent haemodialysis involves dialysing with higher flow rates than CRRT for defined periods of time.  A typical regime is 3-5 hours of dialysis 3 times a week. The high flow rates and rapid fall in plasma osmolality mean that it is only suitable for patients who are cardiovascularly stable. It forms the basis of long term RRT for chronic renal failure but is not often used in the critical care setting.
  • 20. Major complications of IHD Systemic hypotension Arrhythmia Hypoxaemia Haemorrhage Infection Line-related complications(e.g. pneumothorax) Seizure or dialysis disequilibrium Pyrogen reaction or haemolysis ?Delay in recovery of renal function
  • 22. SCUF • High flux membranes • Up to 24 hrs per day • Objective VOLUME control • NotNot suitable for solute clearance • Blood flow 50-200 ml/min • UF rate 2-8 ml/min • High flux membranes • Up to 24 hrs per day • Objective VOLUME control • NotNot suitable for solute clearance • Blood flow 50-200 ml/min • UF rate 2-8 ml/min
  • 23. CAVVH • Extended duration up to weeks • High flux membranes • Mainly convectiveconvective clearance • UF > volume control amount • Excess UF replacedreplaced • Replacement pre- or post-filter • Blood flow 50-200 ml/min • UF rate 10-60 ml/min • Extended duration up to weeks • High flux membranes • Mainly convectiveconvective clearance • UF > volume control amount • Excess UF replacedreplaced • Replacement pre- or post-filter • Blood flow 50-200 ml/min • UF rate 10-60 ml/min
  • 24. CAVVHD • Mid/high flux membranes • Extended period up to weeks • DiffusiveDiffusive solute clearance • Countercurrent dialysate • UF for volume control • Blood flow 50-200 ml/min • UF rate 1-8 ml/min • Dialysate flow 15-60 ml/min • Mid/high flux membranes • Extended period up to weeks • DiffusiveDiffusive solute clearance • Countercurrent dialysate • UF for volume control • Blood flow 50-200 ml/min • UF rate 1-8 ml/min • Dialysate flow 15-60 ml/min
  • 25. Other Benefits of CRRT  Its ability to reduce energy expenditure by cooling the febrile patient, in the patient with heart failure resistant to diuretics, continuous ultrafiltration can produce a rise in cardiac index,while avoiding a fall in arterial pressure. The haemodynamic improvement is mostlydue to a change in preload which optimises myocardial contractility onthe Starlingcurve
  • 26. Sustained low efficiency dialysis  aims to combine the logistic and cost advantages of IHD with the relative cardiovascular stability of CRRT.  Treatments are intermittent but usually daily and with longer session durations than conventional IHD. Solute and fluid removal are slower than IHD, but faster than CRRT.
  • 28. WHICH FORM OF RRT SHOULD WE USE? What we want to remove from the plasma
  • 29. 2. The patient`s cardiovascular status • CRRT causes less rapid fluid shifts and is the preferred option if there is any degree of cardiovascular instability. 3. The availability of resources • CRRT is more labour intensive and more expensive than IHD • Availability of equipment may dictate the form of RRT. 4. The clinician`s experience • It is wise to use a form of RRT that is familiar to all the staff involved. 5. Other specific clinical considerations • Convective modes of RRT may be beneficial if the patient has septic shock • CRRT can aid feeding regimes by improving fluid management • CRRT may be associated with better cerebral perfusion in patients with an acute brain injury or fulminant hepatic failure.
  • 30. Vascular access in HD/CRRT Site Advantages disadvantages IJV Straight access Swings in flow associated with respiration. Subclavian Least association with infection. Most comfortable Swings in flow as above. Subclavian vein stenosis if catheter indwelling for a long time. Risks of pneumothorax Femoral Ease of access Infection rates high.
  • 31. Dialysate Fluid  Bicarbonate buffer solutions is used in IHD to replenish serum bicarbonate levels and neutralise metabolic acids that are usually present in patients with renal failure. Acetate buffer solutions present the body with a large acetate load to be metabolised by the skeletal muscle. In critically ill patients the acetate levels rise due to decreased skeletal muscle metabolism. Increased acetate levels have been associated with hypotension and hypoxia due to its negative inotrope effect and vasodilatation Lactate buffer soulutions
  • 33. Extra corporeal circuit Most CRRT techniques utilise a pump driven venovenous circuit as this provides a high constant flow rate
  • 34. Anticoagulation extracorporeal circuit will activate coagulation pathways and the premature clotting of a filter is a common problem. Even a small amount of clot formation will reduce filter performance. NON-PHARMACOLOGICAL MEASURES 1. adequate central venous pressure, 2. optimising vascular access 3. adding a proportion of the replacement fluid to the patients blood before it passes through the haemofilter (this is predilution)
  • 35. GUIDELINES FOR NO ANTICOAGULATION There is a already a degree of coagulopathy INR > 2-2.5  APTT > 60 seconds  platelet count < 60 x 10³.mm3 There is a high risk of bleeding The patient is receiving activated protein C.
  • 36. PHARMACOLOGICAL MEASURES Unfractionated or low molecular weight heparins Unfractionated heparin (UFH) [5-30kDa] is the most commonly used anticoagulant typical regime involves a 40-70 IU.kg-1 bolus followed by a pre- filterinfusion at 5-10 IU.kg.-1hr-1 It is the most cost effective anticoagulant and is fully reversible with protamine. The APTT should be monitored to avoid excessive anti- coagulation but there is no evidence that elevating the APTT prolongs filter life.
  • 37. Low molecular weight heparins (LMWH) [4.5-6kDa] They are dependant on renal elimination so in this setting their dosing needs to be guided by anti-factor Xa levels (aiming for 0.25-0.35 IU.ml-1  The half life of LMWHs is longer than for UFH (2-6 hrs versus 1.5-3hrs) and their effect can only be partially reversed with protamine. There is not a huge amount of data on the use of LMWH in CRRT and there is no evidence to suggest that they are superior to UFH.
  • 38. Prostaglandins Prostaglandins (prostacyclin or prostaglandin E2) inhibit platelet function and can either be used on their own or in combination with heparin they have a synergistic effect.  short half life (several minutes) so are administered as an infusion (2.5 – 10 ng/kg/.min). The anticoagulant effect stops within 2 hours of discontinuing the infusion The main side effect is vasodilation which may include a reduction in HPV leading to hypoxemia. they are expensive and so are only used as second line therapy
  • 39. Regional citrate anticoagulation It is an effective therapy especially when there is an increased risk of bleeding. It is alternative to heparin Sodium citrate is infused into the circuit pre-filter which chelates calcium and inhibits clot formation. The calcium citrate complex is freely filtered so a calcium infusion is required post-filter. This form of anticoagulation is limited by the metabolic derangements that it can cause: Hypocalcaemia, hypomagnesaemia , hypernatraemia , metabolic alkalosis (citrate is metabolised to bicarbonate), metabolic acidosis (caused by the citrate especially if the body`s citrate handling is impaired e.g.
  • 40. Filters Filters are either cellulose-based or synthetic. Synthetic filters such as polysulphone and polyamide are more biocompatible and are higher-flux membranes so seem more suitable for CRRT high-flux membranes with a surface area of 0.6– 1.2m2 and a pore size allowing the passage of molecules up to 50,000 Daltons
  • 41. Properties Biocompatibility o The degree to which the membrane will activate the patient`s inflammatory and coagulation pathways. o The greater the biocompatibility of a membrane the less activation it will cause Flux o The permeability of the filter. High flux membranes are hydrophobic and may have more or larger pores allowing more water and solute to move across the membrane.
  • 42. Adsorption o The ability of larger solutes to adhere to the surface of the membrane. o A highly adsorptive membrane offers the potential benefit of adsorbing mid sized molecules including inflammatory mediators but only until it is saturated with them (usually after the first few hours) Thickness o Thinner membranes allow greater movement of solute by diffusion and also favour convective movement Surface area o The surface area of the membrane determines the available area for diffusion and ultrafiltration
  • 43. Complications common to IHD, CRRT, and hybrid therapies 1. Complications related to the vascath (including line-related sepsis) 2. Haemodynamic instability 3. Air emboli 4. Platelet consumption 5. Blood loss 6. Electrolyte imbalances 7. Hypothermia 8. Effects of anticoagulation (bleeding or specific side-effects of the anticoagulant used e.g. heparin induced thrombocytopenia).
  • 44. Adequacy of Dialysis  Precise standards and goals of dialysis adequacy are based on the clearance of urea.  The volume of distribution of urea reflects the total body water.  Mathematical modeling based on the changing blood concentrations
  • 45. Dialysis dose 1. Measuring fractional reduction of BUN with each dialysis. Measured by volume adjusted fractional clearance of urea. K*t ÷ V urea Where K – dialyzer urea clearance t – time on dialysis V – volume of distribution of urea
  • 46. Dialysis dose 2. Measurement of urea removed through each dialysis. % of reduction in urea during single hemodialysis treatment – Urea reduction ratio [1-(post dialysis BUN concentration) ] x 100 (pre dialysis BUN concentration)
  • 47. Care of patients receiving hemodialysis Variable Goals Dialysis dose Urea kinetics model Fluid balance Individualised. Intradialytic weight gain should be less than 5% of IBW Quality Measure endotoxin and bacteria in the dialysate water Anemia Target a Hb of 10-12gms%. Avoid high dose erythropoietin Vascular access Monitoring. To establish AV access rather than indwelling catheters. Bone & Mineral Calcium levels between 8.4-9.5 and a PO4 3.5-5.5mg/dl Blood pressure Optimum targets & strategies not well defined LDL cholesterol <100mg/dl Quality of life indices Support from the medical social worker